You are here



The great breakthrough of this new device, which will go on the market in 2012, is that it reduces patient pain and risk of infection, as well as obtaining data faster and more precisely.


Alfón, previously at Palau Pharma, will head the Catalan company’s preclinical and clinical development of an anti-cancer drug candidate


It would be the first treatment to both slow the development of the disease and reduce the neurologic damage that it causes.


Janus will work to produce a medication to treat drug addiction and a vaccine for pasteurellosis, which affects many species of production animals.


Synergies will allow these two companies to provide integral service, from discovery and patenting through to the market.


The project is a huge breakthrough in the development of technology applied to neuroscience.


Neurofarmagen TDAH® is a genetic analysis that allows doctors to see how a patient will react to the most common attention deficit and hyperactivity disorder drugs and helps evaluate future risks.


The company plans on investing in ten to fifteen science and knowledge projects in Spain, principally through seed capital.


The awards, driven by “la Caixa”, Barcelona Activa, Biocat, Genoma España and the Barcelona Chamber of Commerce, were given out during the Biocat Forum.


The aim of the forum is to exchange ideas and opinions on the challenges and opportunities posed by the arrival of a new generation of drugs.